112883-40-6 Usage
Description
Fmoc-Met-OH, also known as N-Fmoc-D-methionine, is an N-Fmoc-protected form of D-Methionine, which is an isomer of L-Methionine. It is a light yellow solid and is known for its cytoprotective properties against various harmful agents.
Uses
Used in Pharmaceutical Industry:
Fmoc-Met-OH is used as a cytoprotectant for its ability to protect cells against the harmful effects of Cisplatin, an anticancer agent. It is particularly effective in preventing noiseand drug-induced hearing loss, as well as hair loss, which may be caused by Cisplatin or aminoglycosides.
Used in Research and Development:
Fmoc-Met-OH is used as a research compound for studying the effects of D-Methionine and its potential applications in various fields, including pharmaceuticals, biotechnology, and chemical synthesis.
Used in Chemical Synthesis:
Fmoc-Met-OH is used as a protected amino acid in the synthesis of peptides and other biomolecules, where the Fmoc group provides protection during the synthesis process and can be removed when needed to reveal the free amino acid.
Check Digit Verification of cas no
The CAS Registry Mumber 112883-40-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,1,2,8,8 and 3 respectively; the second part has 2 digits, 4 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 112883-40:
(8*1)+(7*1)+(6*2)+(5*8)+(4*8)+(3*3)+(2*4)+(1*0)=116
116 % 10 = 6
So 112883-40-6 is a valid CAS Registry Number.
InChI:InChI=1/C20H21NO4S/c1-26-11-10-18(19(22)23)21-20(24)25-12-17-15-8-4-2-6-13(15)14-7-3-5-9-16(14)17/h2-9,17-18H,10-12H2,1H3,(H,21,24)(H,22,23)/t18-/m1/s1
112883-40-6Relevant articles and documents
Novel chiral stationary phases based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin combining cinchona alkaloid moiety
Zhu, Lunan,Zhu, Junchen,Sun, Xiaotong,Wu, Yaling,Wang, Huiying,Cheng, Lingping,Shen, Jiawei,Ke, Yanxiong
, p. 1080 - 1090 (2020/05/25)
Novel chiral selectors based on 3,5-dimethyl phenylcarbamoylated β-cyclodextrin connecting quinine (QN) or quinidine (QD) moiety were synthesized and immobilized on silica gel. Their chromatographic performances were investigated by comparing to the 3,5-dimethyl phenylcarbamoylated β-cyclodextrin (β-CD) chiral stationary phase (CSP) and 9-O-(tert-butylcarbamoyl)-QN-based CSP (QN-AX). Fmoc-protected amino acids, chiral drug cloprostenol (which has been successfully employed in veterinary medicine), and neutral chiral analytes were evaluated on CSPs, and the results showed that the novel CSPs characterized as both enantioseparation capabilities of CD-based CSP and QN/QD-based CSPs have broader application range than β-CD-based CSP or QN/QD-based CSPs. It was found that QN/QD moieties play a dominant role in the overall enantioseparation process of Fmoc-amino acids accompanied by the synergistic effect of β-CD moiety, which lead to the different enantioseparation of β-CD-QN-based CSP and β-CD-QD-based CSP. Furthermore, new CSPs retain extraordinary enantioseparation of cyclodextrin-based CSP for some neutral analytes on normal phase and even exhibit better enantioseparation than the corresponding β-CD-based CSP for certain samples.